CD274 and non-small cell lung carcinoma: The 4-year follow-up results of the KEYNOTE-189 study also showed that regardless of PD-L1 expression levels, the combination of pembrolizumab and chemotherapy can bring survival benefits in adenocarcinoma of NSCLC.